Author

admin

Browsing

Vince Lanci of Echobay Partners explains what’s driving silver’s record-setting price run.

According to Lanci, who is also a professor at the University of Connecticut and publisher of the GoldFix newsletter on Substack, the London market is facing a liquidity crisis as nations that would typically sell or lend their silver choose to keep the metal at home.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

  • MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.

  • New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.

  • Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the successful completion of a private placement offering (the ‘Offering’) of units (‘Units’) for net proceeds of US$11 million. The initial closing of US$10 million has been completed, with the remaining US$1 million to close on Monday, October 20, 2025.

‘As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S. now enrolling patients, we are pleased to have secured a direct investment of US$11 million to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38, based on the recently reported findings from our ARCHER trial,’ said David Elsley, President and CEO of Cardiol Therapeutics. ‘Topline results from our ARCHER trial demonstrated a significant reduction in LV mass-marking the first evidence of structural and remodeling improvement in patients with myocarditis. This landmark finding represents our second clinical validation in inflammatory heart disease and establishes a key translational link to data published earlier this year in the Journal of the American College of Cardiology, which demonstrated the beneficial effects of the active pharmaceutical ingredient or API in CardiolRx on cardiac structure, inflammation, and fibrosis in a model of heart failure. The ARCHER findings support pursuing an additional Orphan Drug Designation for CardiolRx in myocarditis and advancing the development of our next-generation CRD-38 formulation, which delivers the same API via subcutaneous administration, to target the broader heart failure market. Notably, blockbuster drugs that reduce LV mass have been shown to lower heart failure-related death and hospitalization, underscoring the clinical potential of Cardiol’s differentiated anti-inflammatory mechanism to address a large unmet need in heart failure, where five-year mortality rates still exceed 50%.’

Under the Offering, the Company sold a total of 11 million Units at a price of US$1.00 per Unit. Each Unit consists of one Class A common share of the Company (a ‘Common Share‘) and one-half of one Common Share purchase warrant. Each whole warrant entitles the holder to acquire one additional Common Share at an exercise price of US$1.35 for a period of 24 months from the date of issuance. The warrants include an acceleration provision, allowing the Company to advance their expiry to the 30th day following the issuance of a news release if the daily volume-weighted average trading price of the Common Shares exceeds US$2.00 for five consecutive trading days. Proceeds from the Offering provide cash resources that are anticipated to support operations into the third quarter of 2027.

The securities have not been registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any U.S. state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the ‘United States’ or ‘U.S. persons’ (as such terms are used in Regulation S under the U.S. Securities Act), absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or in compliance with an exemption therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Certain insiders of the Company participated in the Offering. Such participation is considered to be a ‘related-party transaction’ within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related-party participation in the Offering as the fair market value (as determined under MI 61-101) of the subject matter of, and the fair market value of the consideration for, the transaction, insofar as it involved interested parties, did not exceed 25% of the Company’s market capitalization (as determined under MI 61-101).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

The ARCHER Program (NCT05180240) comprises the completed Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward-looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for use in heart failure, the Company’s presentation and publication of the comprehensive ARCHER trial data, the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis, and statements regarding the expected length and scope of funding for the Company’s development plans as a result of the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270946

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

The Government of Ontario started taking applications for resource development projects under its “One Project, One Process” framework on Friday (October 17).

The new process, which Ontario lawmakers introduced in the spring, promises to streamline and reduce the permitting time for selected projects by at least half, introducing a dedicated office to consolidate applications. Under the current system, the permitting process can add up to 15 years to a project’s development cycle, the government stated.

In addition to supporting Ontario’s mining industry, the new framework is also a reaction to policy shifts in the United States under the Trump administration, as his tariff policy affects the Ontario and Canadian economies.

“With President Trump taking direct aim at our economy, it has never been more important to protect Ontario jobs and build the mines that will power our future,” said Stephen Lecce, Minister of Energy and Mines.

The new policy is similar to the national one introduced by Prime Minister Mark Carney in September. That program, which created the Major Projects Office, is geared to support investment and permitting for projects deemed to be in the national interest. The initiative was part of his election platform earlier in the year in response to Trump’s tariffs on imports of Canadian goods.

In a speech to the Peterson Institute of International Economics on Thursday (October 16), Bank of Canada Governor Tiff Macklem stated that Canada’s growth outlook remains “soft.”

He identified several trends that are affecting Canadian and global economies. The first is a slowing of global trade that began in 2010, which then accelerated as Trump increased tariff rates to the highest levels since the 1930s.

The second is a shift away from the US as the world’s largest trading hub, as supply chains strengthen in China and Europe, creating new hubs there. Macklem also noted that, while the US remains dominant in global finance, investors have expressed uncertainty due to its declining trade position and increasing debt load.

For Canada, Macklem said the tariffs have affected cross-border trade and stymied investment into Canadian industries, weakening gross domestic product growth.

Although it’s uncertain if the Bank of Canada will cut its rate when it makes its next policy decision on October 29, Macklem said, “Monetary policy cannot undo the damage of tariffs.” Instead, he suggested that Canada needs to lower barriers to interprovincial trade and focus on projects that increase the export of Canadian goods overseas.

South of the border, Federal Reserve Chairman Jerome Powell gave a speech on Tuesday (October 14) to the National Association of Business Economics in Philadelphia. In his remarks, he said the outlook for the jobs market and inflation has not changed since September, and signaled the likelihood of another rate cut when the Federal Open Market Committee meets on October 28 and 29.

In the days following Powell’s remarks, the price of gold surged to a new record high of US$4,379.13 on Thursday, and silver rose to a new record of US$54.40 per ounce. Both have since retreated, but remain elevated.

For more on what’s moving markets this week, check out our top market news round-up.

Markets and commodities react

Canadian equity markets were down this week.

The S&P/TSX Composite Index (INDEXTSI:OSPTX) lost 0.71 percent over the week to close Friday at 30,108.48.

The S&P/TSX Venture Composite Index (INDEXTSI:JX) fared worse, ending the week down 3.85 percent at 965.58. The CSE Composite Index (CSE:CSECOMP) also fell this week, shedding 5.33 percent to close out the week at 179.76.

The gold price set another new record, reaching an intraday high of US$4,379.13 per ounce in early morning trading Friday EST before retreating to US$4,252.69 by Friday’s close. Ultimately, gold was up 5.82 percent over the week.

The silver price also gained significantly this week, again breaking its own all-time high in early trading Friday when it reached US$54.47 per ounce. However, it had pulled back US$51.76 by 4:00 p.m. EDT Friday, posting a weekly gain of 3.46 percent.

The copper price was flat on the week, down just 0.2 percent to US$5.03 per pound.

The S&P Goldman Sachs Commodities Index (INDEXSP:SPGSCI) fell 2.23 percent to end Friday at 539.84.

Top Canadian mining stocks this week

How did mining stocks perform against this backdrop?

Take a look at this week’s five best-performing Canadian mining stocks below.

Stocks data for this article was retrieved at 4:00 p.m. EDT on Friday using TradingView’s stock screener. Only companies trading on the TSX, TSXV and CSE with market caps greater than C$10 million are included. Mineral companies within the non-energy minerals, energy minerals, process industry and producer manufacturing sectors were considered.

1. JZR Gold (TSXV:JZR)

Weekly gain: 112.77 percent
Market cap: C$28.95 million
Share price: C$0.50

JZR Gold is a gold company with exposure to the Vila Nova gold project, located in Amapá, Brazil, through a joint venture royalty agreement with the project’s operator, ECO Mining Oil & Gaz Drilling and Exploration.

JZR received a 50 percent net profit interest in the Vila Nova project following the completion of payments totaling US$6 million to ECO in January 2023. The funds were used to advance the project and construct an 800 metric ton per day bulk sampling gravimetric mill at the site.

According to JZR, the funding is considered a loan and will be “repaid to the Company from the proceeds of the sale of any products, prior to the distribution of any profits.”

The project holds approximately 9 million metric tons of gold tailings grading an average of 2.47 grams per metric ton (g/t) gold from historic operations. The companies plan to reprocess the tailings to generate near-term cash flow that will fund further exploration at the site, anticipating production of 2 kilograms of gold per day.

Shares gained this week alongside the October 14 news that ECO produced the first gold concentrate from the Vila Nova gold project’s mill. JZR said that ECO has begun to stockpile material at the mill site as it continues testing and optimization, with the goal of improving efficiency and increasing throughput.

2. Austral Gold (TSXV:AGLD)

Weekly gain: 90 percent
Market cap: C$75.37 million
Share price: C$0.095

Austral Gold is a gold production company operating two mines in Latin America.

Its Guanaco – Amancaya mine complex in Chile is its primary operation, hosting a 1,500 metric ton per day milling circuit, a 3,000 metric ton per day crushing circuit and a heap leaching processing plant. In 2024, the complex produced 15,138 ounces of gold and 37,154 ounces of silver.

Austral’s other operation is the Casposo – Manantiales complex in Argentina, which hosts a 1,100 metric ton per day mill and a dry-stack tailings facility. The mine had been on care and maintenance since 2019, during which time Austral worked on exploration at the site, along with its refurbishment plan to restart operations.

Shares in Austral rose this week following a pair of announcements on Tuesday.

The first was a report that Austral has resumed production at Casposo, currently sourcing material from the existing stockpiles. The company said it plans to transition to open-pit mining and is in negotiations with a contractor to finalize an agreement.

The company produced 230 gold equivalent ounces of doré during the commissioning phase, which began in December 2024, according to the release. It expects Casposo to produce 4,000 to 6,000 gold equivalent ounces during Q4.

In the other release, Austral provided an updated mineral reserve estimate for Casposo reporting proven and probable gold contained to be 80,000 ounces of gold and 3.28 million ounces of silver with average grades of 1.31 g/t gold and 58.52 g/t silver from 2.15 million metric tons of ore.

3. Resouro Strategic Metals (TSXV:RSM)

Weekly gain: 88.64 percent
Market cap: C$29.14 million
Share price: C$0.415

Resouro Strategic Metals is a polymetallic exploration and development company working to advance its mineral properties in Brazil.

Its Tiros rare earth metals and titanium project is located in Minas Gerais, Brazil, and comprises 28 mineral rights covering an area of 497 square kilometers.

According to a May 2025 technical report, the site hosts a measured and indicated resource of 1.4 billion metric tons of ore grading 12 percent titanium dioxide and 4,000 parts per million of total rare earth content.

The company also owns the Novo Mundo gold project located in the Alta Floresta gold province in Central Brazil. It consists of three licenses totaling 167 square kilometers.

On Tuesday, Resouro provided an update to its ongoing private placement, noting that it had received subscription agreements and expects to close in the next week.

4. Nio Strategic Metals (TSXV:NIO)

Weekly gain: 75 percent
Market cap: C$16.24 million
Share price: C$0.175

Nio Strategic Metals is an exploration company working to advance its assets in Québec, Canada.

Its primary focus has been on its Oka rare earth and critical minerals project. The property hosts a past-producing niobium mine and several nearby mineralized zones.

According to the project page, Oka’s total measured and indicated resource is 10.63 million metric tons of ore at an average grade of 0.65 percent niobium oxide.

While the company did not release any news this week, shares in Nio Strategic Metals rose significantly.

5. Boron One (TSXV:BONE)

Weekly gain: 71 percent
Market cap: C$14.92 million
Share price: C$0.06

Boron One is an exploration company focused on advancing its Piskanja project located near Belgrade, Serbia.

The asset hosts two primary densely mineralized zones with gently undulating borate beds. The company was initially granted its exploration license in 2010, with the exclusive right to apply for a mining license.

In a preliminary economic assessment for the project released in June 2022, Boron One, then named Erin Ventures, reported an economic case with an after-tax, net present value of US$524.9 million with an internal rate of return of 78.7 percent and a payback period of 12 months.

It also provided a mineral resource statement that demonstrated a measured and indicated resource of 2.36 million metric tons of boric oxide from 6.87 million metric tons of ore with an average grade of 34.36 percent boric oxide.

The most recent news from the project came on September 26 when the company provided an update on its application for a mining license, noting the Ministry of Mining has requested amendments to the company’s application before it can be approved.

Boron One said it is preparing the revised version “as quickly as possible.”

FAQs for Canadian mining stocks

What is the difference between the TSX and TSXV?

The TSX, or Toronto Stock Exchange, is used by senior companies with larger market caps, and the TSXV, or TSX Venture Exchange, is used by smaller-cap companies. Companies listed on the TSXV can graduate to the senior exchange.

How many mining companies are listed on the TSX and TSXV?

As of May 2025, there were 1,565 companies listed on the TSXV, 910 of which were mining companies. Comparatively, the TSX was home to 1,899 companies, with 181 of those being mining companies.

Together, the TSX and TSXV host around 40 percent of the world’s public mining companies.

How much does it cost to list on the TSXV?

There are a variety of different fees that companies must pay to list on the TSXV, and according to the exchange, they can vary based on the transaction’s nature and complexity. The listing fee alone will most likely cost between C$10,000 to C$70,000. Accounting and auditing fees could rack up between C$25,000 and C$100,000, while legal fees are expected to be over C$75,000 and an underwriters’ commission may hit up to 12 percent.

The exchange lists a handful of other fees and expenses companies can expect, including but not limited to security commission and transfer agency fees, investor relations costs and director and officer liability insurance.

These are all just for the initial listing, of course. There are ongoing expenses once companies are trading, such as sustaining fees and additional listing fees, plus the costs associated with filing regular reports.

How do you trade on the TSXV?

Investors can trade on the TSXV the way they would trade stocks on any exchange. This means they can use a stock broker or an individual investment account to buy and sell shares of TSXV-listed companies during the exchange’s trading hours.

Article by Dean Belder; FAQs by Lauren Kelly.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

This week was marked by strong, event-driven volatility across the tech sector.

Market moves were shaped by artificial intelligence (AI) infrastructure announcements, semiconductor earnings, signals of macroeconomic stress and escalating tensions between the US and China.

Effects of the US government shutdown, coupled with renewed trade tensions between the world’s largest tech markets, weighed on global equities. Quarterly results from regional banks eased earlier concerns about credit risks after Zions Bancorp (NASDAQ:ZION) and Western Alliance (NYSE:WAL) disclosed loan issues related to apparent fraud.

Wall Street ultimately saw weekly gains, despite a midweek selloff that impacted high-value, high-risk sectors.

Hardware and infrastructure were the core positive contributors in the tech sector, reflecting the ongoing AI supercycle investment theme fueled by chip production and data center buildouts.

Semiconductor stocks were the standout performers, boosted by record earnings reports from Taiwan Semiconductor Manufacturing Company (TSMC) (NYSE:TSM) on Tuesday (October 14) and ASML Holding (NASDAQ:ASML) on Wednesday (October 15). Broadcom (NASDAQ:AVGO) and NVIDIA (NASDAQ:NVDA) also rose alongside TSMC, contributing to PHLX Semiconductor Sector’s (INDEXNASDAQ:SOX) 1.2 percent rebound on Thursday (October 16).

Advanced Micro Devices’ (NASDAQ:AMD) deal with Oracle (NYSE:ORCL) to deploy 50,000 GPUs, which was announced the same day as TSMC’s earnings, added a competitive dynamic that sparked selective volatility among chipmakers; at the same time, it underscored strong AI-driven hardware demand across the sector.

In consumer hardware, Apple’s (NASDAQ:AAPL) product launch was notable, but not the primary market mover.

Data centers also had a big impact, highlighted by Microsoft’s (NASDAQ:MSFT) US$14 billion Texas AI data center partnership with Nscale, and Brookfield Asset Management’s (TSX:BAM,NYSE:BAM) US$5 billion investment in Bloom Energy’s (NYSE:BE) fuel cell technology for powering AI-focused data centers. Oracle is forecasting acceleration in its AI data center business, indicating expanding hardware-backed infrastructure demand

Software and cloud-native company movements were more mixed, with gains from Salesforce (NYSE:CRM), but declines from others like Meta Platforms (NASDAQ:META) and Palantir Technologies (NASDAQ:PLTR).

3 tech stocks that moved markets this week

1. Broadcom (NASDAQ:AVGO)

Broadcom shares surged nearly 10 percent on Monday (October 13) after OpenAI announced a multi-year agreement to co-develop custom AI GPUs. The collaboration will focus on deploying 10 gigawatts of custom AI accelerators designed by OpenAI and built by Broadcom, with deployment set to start in H2 2026 and continue through 2029.

Later, multiple reports emerged citing individuals claiming that OpenAI is also partnering with Arm Holdings (NASDAQ:ARM) to produce custom CPUs to work alongside its Broadcom co-designed chip.

Shares of Arm also advanced by over 11 percent.

2. Advanced Micro Devices (NASDAQ:AMD)

Oracle and AMD also announced a major partnership this week, where Oracle will deploy 50,000 AMD-powered MI450 GPUs in its cloud infrastructure starting in the third quarter of 2026, with plans for ongoing expansion.

AMD’s share price rose by over 9 percent on the news, with the deal creating competitive pressure for rival chipmakers like NVIDIA. Meanwhile, Oracle shares declined by almost 7 percent on Friday (October 17) after the firm’s CEO, Clay Magouryk, provided an upbeat projection to analysts, indicating that the deployment of 50,000 AMD-powered MI450 GPUs will significantly accelerate Oracle’s AI business growth.

However, analysts highlighted the potential for a significantly high CAPEX, possibly leading to negative free cashflow totaling more than US$26 billion over the next three fiscal years.

3. Salesforce (NYSE:CRM)

Shares of Salesforce rose by almost 4 percent on Thursday after the company announced a revenue target of US$60 billion by 2030 during its Investor Day at Dreamforce event on Wednesday.

Salesforce plans to achieve this ambitious target through accelerated adoption of AI-powered cloud platforms and ongoing innovation in enterprise software services, as well as expanded use of generative AI across its CRM, analytics, and automation suites.

Broadcom, Salesforce and AMD performance, October 14 to 17, 2025.

Chart via Google Finance.

Tech ETF performance

This week, the iShares Semiconductor ETF (NASDAQ:SOXX) advanced by 1.94 percent, while the Invesco PHLX Semiconductor ETF (NASDAQ:SOXQ) saw a weekly gain of 1.66 percent.

The VanEck Semiconductor ETF (NASDAQ:SMH) increased by 1.59 percent.

These modest gains occurred against a backdrop of heightened volatility, indicating ongoing optimism in the long-term growth of the semiconductor industry.

Other tech market news

            Tech news to watch next week

            Next week brings quarterly earnings from major tech firms Tesla (NASDAQ:TSLA) and IBM (NYSE:IBM) on October 22, followed by Intel (NASDAQ:INTC) and Amazon (NASDAQ:AMZN) on October 23.

            Any new developments in US-China relations, potential technology export restrictions or antitrust actions could significantly affect tech stock performance. Market watchers will also be on the lookout for any indication of an end to the US government shutdown.

            Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

            This post appeared first on investingnews.com

            /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

            finlay minerals ltd. (TSXV: FYL,OTC:FYMNF) (OTCQB: FYMNF) (‘Finlay’ or the ‘Company’) is pleased to announce that it has closed its non-brokered private placement (the ‘Private Placement’), previously announced on October 6, 2025, consisting of the issuance of: (i) 10,633,999 flow-through units of the Company (each, a ‘FT Unit’) at a price of $0.15 per FT Unit, and (ii) 883,000 non-flow-through units of the Company (each, a ‘NFT Unit’) at a price of $0.13 per NFT Unit, for aggregate gross proceeds to the Company of $1,709,890.

            Each FT Unit is comprised of one common share of the Company issued on a flow-through basis under the Income Tax Act (Canada) (a ‘FT Share‘) and one-half of one non-flow-through common share purchase warrant (each whole warrant, a ‘Warrant‘). Each Warrant is exercisable by the holder thereof to acquire one non-flow-through common share of the Company (a ‘NFT Share‘) at an exercise price of $0.25 per NFT Share until October 17, 2027.

            Each NFT Unit is comprised of one NFT Share and one Warrant with identical terms to the Warrants underlying the FT Units.

            The Company intends to use the gross proceeds of the Private Placement for exploration of the Company’s SAY, JJB and Silver Hope properties, and for general working capital purposes, as more particularly described in the offering document for the Private Placement. The Company will use the gross proceeds from the issuance of FT Shares to incur ‘Canadian exploration expenses’ and qualify as ‘flow-through critical mineral mining expenditures’, as such terms are defined in the Income Tax Act (Canada).

            The Private Placement was conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The securities issued to purchasers in the Private Placement are not subject to a hold period under applicable Canadian securities laws. The Private Placement is subject to final approval of the TSX Venture Exchange.

            The Company paid aggregate cash finder’s fees of $96,550.78 and issued 648,358 non-transferable finder warrants (each a ‘Finder Warrant‘) to arm’s length finders of the Company, as compensation for identifying purchasers in the Private Placement. Each Finder Warrant entitles the holder thereof to purchase one NFT Share at an exercise price of $0.25 per NFT Share until October 17, 2027. The Finder Warrants and the NFT Shares issued on exercise thereof are subject to a hold period expiring on February 18, 2026 in accordance with applicable securities laws.

            This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder.

            About finlay minerals ltd.

            Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. All of the properties are located in areas of recent copper-gold porphyry discoveries.

            Finlay trades under the symbol ‘FYL’ on the TSXV and under the symbol ‘FYMNF’ on the OTCQB. For further information and details, please visit the Company’s website at www.finlayminerals.com 

            On behalf of the Board of Directors,

            Robert F. Brown,
            Executive Chairman of the Board

            Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

            Forward-Looking Information: This news release includes certain ‘forward-looking information’ and ‘forward-looking statements’ (collectively, ‘forward-looking statements’) within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as ‘expect’, ‘plan’, ‘anticipate’, ‘project’, ‘target’, ‘potential’, ‘schedule’, ‘forecast’, ‘budget’, ‘estimate’, ‘intend’ or ‘believe’ and similar expressions or their negative connotations, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’, ‘should’ or ‘might’ occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the final approval for the Private Placement from the TSXV and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay’s proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements, and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law. 

            SOURCE finlay minerals ltd.

            View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2025/17/c8773.html

            News Provided by Canada Newswire via QuoteMedia

            This post appeared first on investingnews.com

            MILAN — Giorgio Armani has appointed deputy managing director Giuseppe Marsocci as chief executive with immediate effect, the Italian fashion house said on Thursday, confirming media reports.

            Marsocci, who has been with the company for 23 years, serving as global chief commercial officer for the past six years, steps into the role previously held by founder Giorgio Armani, who died in September.

            Armani kept a tight grip on the fashion empire he set up 50 years ago, but a new structure is emerging for its next phase.

            Marsocci will oversee the planned sale of a 15% stake, with priority to be given to the luxury conglomerate LVMH.PA, beauty heavyweight L’Oreal OREP.PA, eyewear leader EssilorLuxottica ESLX.PA or another group of “equal standing,” as outlined in Armani’s will.

            “His international professional experience, deep knowledge of the sector and the company, discretion, loyalty, and team spirit, together with his closeness to Mr. Armani in recent years, make Giuseppe the most natural choice to ensure continuity with the path outlined by the founder,” said Armani‘s partner and head of men’s design, Pantaleo Dell’Orco, who has taken on the role of chairman.

            Dell’Orco has also recently been appointed to chair the Giorgio Armani Foundation, which controls 30% of the voting rights of his business empire. Dell’Orco already controls 40% of the luxury group’s voting rights.

            The appointment of Marsocci, 61, was unanimously proposed by the Giorgio Armani Foundation, the luxury group said.

            Giorgio Armani’s niece Silvana, head of women’s style, will be appointed vice president, according to the statement.

            This post appeared first on NBC NEWS

            NASA is once again considering Elon Musk ally Jared Isaacman for the administration’s top role.

            The private astronaut had been nominated for the role earlier this year, but the White House yanked that nomination as cracks formed in President Donald Trump’s relationship with Musk.

            Secretary Duffy and Jared Isaacman had an excellent meeting,’ NASA press secretary Bethany Stephens first told Reuters in a statement this week.

            She added in a statement to Fox News Digital: ‘At President Trump’s direction, Secretary [Sean] Duffy in his capacity as acting NASA Administrator, is meeting with and vetting several candidates for the permanent role.’ 

            The nomination was pulled on May 31, one day after the White House held a farewell press conference for Musk, the SpaceX and Tesla CEO who led Department of Government Efficiency (DOGE) efforts.

            Trump announced on social media at the time he was pulling the nomination for Isaacman, a commercial astronaut and founder and CEO of payment processing company Shift4 Payments after ‘a thorough review of prior associations.’

            Trump also said he would unveil a ‘new Nominee who will be Mission aligned, and put America First in Space.’

            Isaacman’s affiliations with Musk include being an investor in SpaceX, in addition to leading two private spaceflight missions with SpaceX, including Inspiration4. The 2021 Inspiration4 mission was the first time an all-civilian crew orbited Earth.

            The billionaire investor flew twice to space in the company’s capsules.

            He had spent months navigating the Senate’s confirmation process at the time his nomination was yanked, balancing NASA’s multi-billion-dollar strategy to return to the moon first and its focus on Mars. NASA recently unveiled plans to develop a nuclear reactor on the moon. 

            Isaacman said he suspected his ties to Musk were part of the decision, noting the call came the same day Musk’s tenure with DOGE concluded.

            ‘I don’t need to play dumb on this,’ Isaacman said on the ‘All In’ podcast. ‘I don’t think that the timing was much of a coincidence, that there were other changes going on the same day.

            ‘There were some people that had some axes to grind, I guess, and I was a good, visible target.’

            Tensions between Trump and Musk came to a head when Musk came out against the ‘Big Beautiful Bill,’ Trump’s massive tax and spending package.

            Ties between the pair are seemingly on the mend. They shook hands and chatted at Charlie Kirk’s funeral in Glendale Arizona last month.

            ‘We had a little conversation,’ Trump said. ‘We had a very good relationship, but it was nice that he came over.’

            This post appeared first on FOX NEWS

            The top Democrat in the House of Representatives attacked White House Press Secretary Karoline Leavitt with a slew of insults on Friday.

            House Minority Leader Hakeem Jeffries, D-N.Y., accused Republican officials of unjustly going after Democrats amid a controversy over a swastika flag found in a House GOP lawmaker’s office this week, though the lawmaker denied he or his staff played any role. Jeffries made the comments during a press conference with reporters on day 17 of the ongoing government shutdown.

            ‘You’ve got Karoline Leavitt, who’s sick. She’s out of control. And I’m not sure whether she’s just demented, ignorant, a stone-cold liar, or all of the above,’ Jeffries said.

            ‘But the notion that an official White House spokesperson would say that the Democratic Party consists of terrorists, violent criminals, and undocumented immigrants makes no sense, that this is what the American people are getting from the Trump administration in the middle of a shutdown.’

            Fox News Digital reached out to the White House for a response.

            Jeffries had been asked about the swastika, which was reportedly embedded into a small American flag that was hanging on a cork board in the office of Rep. Dave Taylor, R-Ohio. It was first reported by a local Ohio social media reporter who goes by the X handle ‘The Rooster.’

            Taylor said in a statement to Fox News that several offices were targeted with the flag, which he said was the work of an ‘unidentified group’ in a coordinated opposition campaign.

            ‘New details have emerged from a coordinated investigation into the vile symbol that appeared in my office. Numerous Republican offices have confirmed that they were targeted by an unidentified group or individual who distributed American flags bearing a similar symbol, which were initially indistinguishable from an ordinary American flag to the naked eye,’ Taylor said. 

            ‘After a full-scale internal investigation, I am confident that no employee of this office would knowingly display such a despicable image, and the flag in question was taken down immediately upon the discovery of the obscured symbol it bore.’

            It’s not immediately clear why the events made Jeffries invoke Leavitt specifically, however.

            Tensions have run high on both sides as the shutdown drags on, and the standoff shows no signs of slowing down.

            In fact, it’s expected to roll into its fourth week after Senate Democrats blocked the GOP’s federal funding measure for a fourth time on Thursday before leaving Washington for the weekend.

            Republicans put forward last month a seven-week extension of fiscal year (FY) 2025 funding levels, called a continuing resolution (CR), aimed at giving congressional negotiators more time to strike a long-term deal for FY2026.

            But Democrats in the House and Senate were infuriated by being sidelined in those talks. The majority of Democrats are refusing to accept any deal that does not include serious healthcare concessions, at least extending COVID-19 pandemic-era Obamacare subsidies that are set to expire at the end of this year.

            Fox News’ Chad Pergram contributed to this report.

            This post appeared first on FOX NEWS

            Former White House National Security Advisor John Bolton pleaded not guilty Friday to all 18 counts related to the improper handling of classified materials after surrendering to federal authorities in Maryland.

            U.S. Magistrate Judge Timothy Sullivan explained the charges to Bolton and asked if he understood them and the potential penalties of up to ten years per count and a maximum fine of $250,000 per count. 

            ‘I do your honor,’ Bolton said during his arraignment at the federal courthouse in Greenbelt, Md. 

            He was indicted on eight counts of transmission of national defense information and ten counts of retention of national defense information.

            ‘From on or about April 9, 2018, through at least on or about August 22, 2025, BOLTON abused his position as National Security Advisor by sharing more than a thousand pages of information about his day-to-day activities as the National Security Advisor — including information relating to the national defense which was classified up to the TOP SECRET/SCI level — with two unauthorized individuals, namely Individuals 1 and 2,’ the indictment reads. ‘BOLTON also unlawfully retained documents, writings, and notes relating to the national defense, including information classified up to the TOP SECRET/SCI level, in his home in Montgomery County, Maryland.’

            The documents Bolton allegedly transmitted were sent to two individuals unauthorized to view classified documents, the indictment said.

            Those documents, according to the indictment, revealed intelligence about future attacks by an adversarial group in another country, a liaison partner sharing sensitive information with the U.S. intelligence community, intelligence that a foreign adversary was planning a missile launch in the future and a covert action in a foreign country that was related to sensitive intergovernmental actions, among other information.

            ‘The FBI’s investigation revealed that John Bolton allegedly transmitted top secret information using personal online accounts and retained said documents in his house in direct violation of federal law,’ said FBI Director Kash Patel. ‘The case was based on meticulous work from dedicated career professionals at the FBI who followed the facts without fear or favor. Weaponization of justice will not be tolerated, and this FBI will stop at nothing to bring to justice anyone who threatens our national security.’

            Photographers snapped images of Bolton leaving his home in Bethesda, Md., earlier Friday. He was later captured on news cameras walking into the federal courthouse. 

            When asked by Fox News at the scene if he had a comment, Bolton just walked into the building.

            Bolton’s Maryland home had been raided by FBI agents in August. That search was focused on classified documents that investigators believed Bolton possessed. 

            ‘Now, I have become the latest target in weaponizing the Justice Department to charge those he deems to be his enemies with charges that were declined before or distort the facts,’ Bolton said in a statement Friday to The Associated Press, referencing President Donald Trump.

            Bolton’s attorney, Abbe Lowell, added in a statement to the AP that the ‘underlying facts in this case were investigated and resolved years ago.’

            ‘Bolton kept diaries — that is not a crime,’ he said, noting that Bolton ‘did not unlawfully share or store any information.’

            Lowell told the AP that the charges Bolton faces are linked to portions of Bolton’s personal diaries and included unclassified information that was shared with only immediate family members. Lowell also said this was known to the FBI dating back to at least 2021.

            This is a developing story. Please check back for updates.

            This post appeared first on FOX NEWS

            Trump-appointed lawyers leading key federal court districts in blue states have become wrapped up in legal disputes that are testing their authority and threatening to undermine criminal cases they are overseeing.

            U.S. Attorney Lindsey Halligan, who brought a high-profile indictment against former FBI Director James Comey in Virginia, is in the hot seat, as are President Donald Trump’s appointees in New Jersey, California and Nevada.

            In a sign of his growing frustration over the matter, Trump wrote in a pair of statements Thursday night that he had ‘eight GREAT Republican U.S. Attorney Candidates’ who did not have a path to Senate confirmation in blue states, blaming the upper chamber’s ‘blue slip’ tradition. He called the precedent, which requires home-state senators to approve of U.S. attorney nominees, ‘stupid and outdated.’

            Vulnerability in Virginia 

            Trump nominated Erik Siebert to be U.S. attorney in the Eastern District of Virginia, but he ousted Siebert in September and blamed it on Siebert securing blue slips from the state’s two Democratic senators. In reality, Siebert opposed bringing criminal charges against two of Trump’s top political nemeses, Comey and New York Attorney General Letitia James.

            At Trump’s direction, Halligan, a former insurance lawyer with no prosecutorial experience, entered the scene within days.

            Halligan brought indictments against both Comey and James, which could now come back to haunt the Department of Justice.

            Josh Blackman, professor at South Texas College of Law, noted that when she charged Comey, Halligan was the lone prosecutor to sign his indictment alleging he made a false statement to Congress. Comey has since told the court that he plans to contest Halligan’s authority because of the unconventional way Trump installed her to lead the U.S. attorney’s office.

            ‘The Halligan issue is central to the James Comey prosecution, and if, for whatever reason, it’s found that she was not properly appointed — she was the only person who signed the Comey indictment — that indictment’s thrown out, so the stakes are actually pretty high,’ Blackman told Fox News Digital.

            The judge could also toss out Comey’s case on other grounds before addressing Halligan’s appointment, which could allow the court to avoid addressing the matter.

            Halligan was also the lone prosecutor to sign James’ bank fraud indictment. By contrast, several prosecutors appeared in court on Thursday for former National Security Adviser John Bolton’s indictment in Maryland and signed onto the 26-page charging document.

            ‘Utterly implausible’ that president can’t choose his appointees

            Halligan is not the only temporary U.S. attorney facing scrutiny. Another Trump ally, Alina Habba, has seen her authority called into question in the U.S. Attorney’s Office in New Jersey, where Democratic Sens. Cory Booker and Andy Kim refuse to support her, creating at least one insurmountable obstacle to her permanent confirmation.

            When Habba’s interim term expired, Trump and Attorney General Pam Bondi used a series of loopholes in federal vacancy laws to bypass the Senate, fire Habba’s court-appointed successor and re-install Habba as ‘acting’ U.S. attorney, which carries a 210-day term.

            Judge Matthew Brann found Habba’s appointment was unlawful, and now the U.S. Court of Appeals for the 3rd Circuit will hear arguments over Habba’s appointment on Monday in a case that could be headed for the Supreme Court.

            In court papers, the DOJ argued federal vacancy laws established by Congress and the Constitution favored the president.

            ‘It is utterly implausible that Congress intended the default to be that the President must rely on career officials who may disagree with his policies to serve as acting political officers during the critical period at the start of an administration,’ DOJ lawyers wrote.

            But the trend of challenging Trump’s workarounds did not stop with Habba.

            More blue state blues

            A federal judge disqualified Sigal Chattah from serving as the temporary U.S. attorney in Nevada, while Acting U.S. Attorney Bill Essayli is facing a court challenge after Trump and Bondi extended his tenure in the Central District of California, where pivotal immigration-related cases are playing out.

            Three sets of defendants facing charges in California are seeking to have their cases tossed on the grounds that Essayli is an invalid appointee. They alleged in court filings that using loopholes to skip over Essayli’s Senate confirmation is following ‘a handbook for circumventing the protections that the Constitution and Congress built against the limitless, unaccountable handpicking of temporary officials.’

            Carl Tobias, professor at University of Richmond law school, told Fox News Digital in August that Trump’s maneuvers to keep his most loyal prosecutors in positions of power defy the spirit of the Constitution.

            ‘It’s good to have that scrutiny from the Judiciary Committee and then on the [Senate] floor, and so hopefully they could return to something like that, but I’m not sure that’s going to happen, and so I think it is troubling,’ Tobias said.

            Although the contentious fight for presidents to push their nominees through the Senate is not new, Blackman said Trump’s escalation of the disputes is uncharted territory and that the issue is ‘two-fold.’

            ‘The first problem is the senators are perhaps not giving deference to Trump’s picks if they don’t have to,’ Blackman said. ‘The second issue is, does the law actually permit these sort of workarounds? And I think Trump is sort of pushing novel grounds. This hasn’t really been tested before like this.’

            This post appeared first on FOX NEWS